On December 17, 2025, Vistagen Therapeutics, Inc. reported that their PALISADE-3 Phase 3 study for fasedienol in treating social anxiety disorder did not meet its main goal, showing no significant difference from placebo (13.6 vs. 14.0 on the distress scale). Despite this, safety results were in line with previous studies.